EUVIMEDEUVIMED entdecken
Open Access

Donafenib vs. lenvatinib combined with transarterial chemoembolization as initial therapy for unresectable hepatocellular carcinoma: a retrospective real-world study

Huzheng Yan, Guohong Li, Chenghao Zhao, Mingan Li, Mingsheng Huang, Huan Liu, Mingming Liu, Zhanwang Xiang

Quantitative Imaging in Medicine and Surgery · 2025-08 · 15 (8) · 7235-7245

DOI: 10.21037/qims-2025-364 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Quantitative Imaging in Medicine and Surgery, 2025-08. Verfasst von Huzheng Yan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The combination of tyrosine kinase inhibitors (TKIs) with transarterial chemoembolization (TACE) holds promise for unresectable hepatocellular carcinoma (HCC). This study aimed to directly compare the efficacy and safety of donafenib (Dona)-TACE vs. lenvatinib (LEN)-TACE as first-line therapies.

Methods

In this retrospective study, 93 unresectable HCC patients (49 Dona-TACE, 44 LEN-TACE; 93% hepatitis B virus-infected) treated between October 2020 and May 2023 were analyzed. Patients received TACE (conventional or drug-eluting beads) combined with Dona (200 mg twice daily) or LEN (8-12 mg/day). Outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). Survival analyses employed Kaplan-Meier and log-rank tests.

Results

Median OS (mOS) was 14.00 months (Dona-TACE) vs. 19.00 months (LEN-TACE) [hazard ratio (HR) =1.25; 95% confidence interval (CI): 0.78-1.99; P=0.330]. Median PFS was 7.37 vs. 5.77 months (HR =0.785; 95% CI: 0.46-1.33; P=0.354), with no significant differences. ORR (55.10% vs. 61.36%, P=0.541) and DCR (75.51% vs. 81.82%, P=0.460) were comparable. Dona-TACE showed significantly lower overall AE rates (any grade: 85.71% vs. 100.00%, P=0.013; grade ≥3: 22.45% vs. 45.45%, P=0.027), including reduced hypertension (2.04% vs. 36.36%, P

Schlagwörter

Stichwörter der Autor:innen

Hepatocellular carcinoma (HCC)donafenib (Dona)lenvatinib (LEN)transarterial chemoembolization (TACE)

Autor:innen und Institutionen

  • Department of Interventional Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Department of Radiology, The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, China.
  • Department of Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Zitieren

APA

Yan, H., Li, G., Zhao, C., Li, M., Huang, M., Liu, H., Liu, M., & Xiang, Z. (2025). Donafenib vs. lenvatinib combined with transarterial chemoembolization as initial therapy for unresectable hepatocellular carcinoma: a retrospective real-world study. Quantitative Imaging in Medicine and Surgery, 15(8), 7235-7245. https://doi.org/10.21037/qims-2025-364

Vancouver

Yan H, Li G, Zhao C, Li M, Huang M, Liu H, et al. Donafenib vs. lenvatinib combined with transarterial chemoembolization as initial therapy for unresectable hepatocellular carcinoma: a retrospective real-world study. Quantitative Imaging in Medicine and Surgery. 2025;15(8):7235-7245. doi:10.21037/qims-2025-364

BibTeX
@article{Yan2025,
  author = {Yan, Huzheng and Li, Guohong and Zhao, Chenghao and Li, Mingan and Huang, Mingsheng and Liu, Huan and Liu, Mingming and Xiang, Zhanwang},
  title = {Donafenib vs. lenvatinib combined with transarterial chemoembolization as initial therapy for unresectable hepatocellular carcinoma: a retrospective real-world study},
  journal = {Quantitative Imaging in Medicine and Surgery},
  year = {2025},
  volume = {15},
  number = {8},
  pages = {7235--7245},
  doi = {10.21037/qims-2025-364}
}
Kostenlos starten →